TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced approximately $85 million in equity and debt financing.
The Company priced a public offering of its common stock for gross proceeds of approximately $25.2 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, the Company granted the underwriters a 30-day option to purchase $3.8 million of additional shares of common stock. All of the shares in the offering are being sold by the Company. The Company anticipates using the net proceeds from the offering to fund the ongoing development of ublituximab and umbralisib, for research and development activities and for general corporate purposes. The offering is expected to close on March 5, 2019 subject to customary closing conditions.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. The underwriter may offer the shares from time to time for sale in one or more transactions on The NASDAQ Capital Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. On February 28, 2019, the last sale price of the shares as reported on The NASDAQ Capital Market was $6.80 per share.
In addition to the above equity financing, the Company also announced yesterday that it has secured a $60 million venture debt facility with Hercules Capital, a leader in customizing debt financing for companies in the life sciences and technology-related markets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.